Background. Isavuconazole (ISA) is a novel broad-spectrum triazole antifungal available as a water-soluble prodrug in IV and oral formulations for treatment of invasive fungal disease. A Phase 3 trial assessed the efficacy and safety of ISA vs voriconazole (VRC) in patients with IMD. Here we report outcomes in a pre-specified subset of patients from this non-inferiority trial, who had proven, probable, or possible pulmonary mold disease (PMD) without other site involvement (lower respiratory tract disease only).
Methods. Patients were randomized 1:1 to receive ISA or VRC for up to 84 days. Dosing regimens were: ISA 200mg IV TID for 2 days, followed by 200mg QD (IV or PO); VRC 6mg/kg IV BID on Day 1, 4mg/kg IV BID on Day 2, then either 4mg/kg IV BID or 200mg PO BID. Eligibility criteria and pre-specified outcomes are available at clinicaltrials.gov, NCT00412893. The primary efficacy endpoint was all-cause mortality by Day 42. All-cause mortality on Day 84, overall success (complete + partial response) at end of treatment (EOT) determined by an independent blinded data review committee were recorded. Safety and tolerability were also assessed, as reported by the Investigator.
Results. Overall 412 patients with proven/probable/possible PMD, primarily caused by Aspergillus spp. (n = 224), were enrolled. Patient characteristics, outcomes, and adverse events (AEs) are presented in the table. Outcomes in patients with proven/probable cases were similar to those with proven/probable/possible infections.
Efficacy and safety in patients with PMD
Parameter ISA (n=200) VRC (n=212) Adjusted difference* % (95% CI) 
